Medtronic Beats Estimates, Lifts FY26 Profit Outlook on Lower Tariff Costs

Medtronic reported first-quarter fiscal 2026 earnings that outpaced Wall Street expectations, posting adjusted earnings of $1.26 a share on revenue of $8.58 billion. Analysts polled by Bloomberg had looked for $1.23 and $8.38 billion, respectively. The medical-device maker’s adjusted operating margin reached 23.6%, also ahead of forecasts. On the back of the stronger start to the year, the Galway-based company lifted its full-year adjusted profit outlook to $5.60–$5.66 per share from $5.50–$5.60 while reiterating guidance for roughly 5% organic revenue growth. It marked the 11th consecutive quarter of mid-single-digit organic sales expansion, driven by demand for cardiac ablation products, diabetes devices and other elective-procedure equipment. Management trimmed the assumed hit from U.S. tariffs to about $185 million, down from a prior estimate of $200–$350 million, helping underpin the higher earnings forecast. Executives said steady volumes of non-urgent surgeries and continued cost-control efforts should support margins through the remainder of the fiscal year.